Medtronic has completed its $650 million acquisition of SPR Therapeutics, a leader in short-term peripheral nerve stimulation (PNS) therapies for pain management. This acquisition adds SPR's FDA-cleared SPRINT® PNS System, a minimally invasive, non-opioid treatment offering up to 60 days of pain relief without permanent implants, to Medtronic's broad pain therapy portfolio. The move aims to expand patient access to innovative pain treatments and supports Medtronic's strategy to enhance its core healthcare technologies. The acquisition is expected to have minimal impact on Medtronic's earnings in fiscal 2027 and become accretive thereafter.
RapidPulse, Inc. secured $48 million in a Series B funding round led by Medtronic and top investors to support clinical trials and development of its next-generation stroke aspiration technology. The funds will complete the TURBO study and help seek ...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
